Table 3.
Mean changes in plasma cytokines, angiogenesis factors, and autotaxin with treatments.
| Cytokines | Baseline values | ASA effect compared to placebo* |
p-value | EPA+DHA effect compared to placebo* |
p-value | EPA+DHA+ASA effect compared to placebo* |
p-value |
|---|---|---|---|---|---|---|---|
| IL-1B | 0.61 (0.3) | 0.21 (0.61) | 0.06 | −0.11 (0.62) | 0.84 | −0.05 | 0.70 |
| IL-6 | 2.47 (1.1) | −0.57 (4.7) | 0.86 | −0.18 (1.26) | 0.63 | −0.98 (5.1) | 0.77 |
| IL-8 | 2.84 (0.9) | −0.1 (3.5) | 0.88 | −0.13 (3.3) | 0.46 | −0.3 (3.73) | 0.43 |
| IL-10 | 2.53 (3.3) | −0.39 (1.4) | 0.31 | −0.52 (1.5) | 0.15 | −1.92 (6.1) | 0.12 |
| MCP-1 | 8.58 (5.8) | −3.8 (13.9) | 0.23 | −4.8 (15.8) | 0.20 | −3.4 (16.7) | 0.57 |
| INF-A | 6.96 (5.7) | 2.6 (5.6) | 0.23 | 0.96 (5.1) | 0.45 | −1.5 (8.94) | 0.96 |
| IFN-G | 36.20 (22.0) | 0.05 (25.2) | 0.84 | −2.3 (28.9) | 0.68 | −3.0 (31.4) | 0.72 |
| G-CSF | 10.44 (8.3) | −0.8 (4.9) | 0.73 | −0.9 (6.2) | 0.68 | −1.1 (5.85) | 0.50 |
| EOTAXIN | 23.26 (13.0) | −4.5 (20.1) | 0.28 | −3.0 (20.8) | 0.70 | −3.5 (18.0) | 0.87 |
| PDGF-BB | 371.56 (206.0) | 14.6 (156.2) | 0.93 | 9.4 (232.3) | 0.40 | 16.7 (298.7) | 0.56 |
| VGEF | 9.33 (7.9) | −2.06 (35.4) | 0.80 | −5.6 (32.1) | 0.41 | −6.1 (33.0) | 0.28 |
| FGF-BASIC | 13.66 (9.5) | 1.4 (7.2) | 0.56 | −0.49 (12.1) | 0.98 | −0.62 (10.7) | 0.75 |
| Autotaxin | 117.76 (18.2) | 1.3 (13.24) | 0.45 | −0.09 (12.8) | 0.82 | −1.21 (9.9) | 0.76 |
All means are differences between the effects of placebo, aspirin, EPA+DHA, or both, on plasma concentrations. Units for the cytokines are picogram/mL and mean flourescenceunits/lL for autotoxin.
p-values were calculated using the Wilcoxon signed-rank test.
*
Change (SD).
When comparing the effects of aspirin to EPA+DHA, aspirin to aspirin+EPA+DHA, and EPA+DHA to EPA+DHA+aspirin, none were statistically significant (p≥0.05) ASA=aspirin.